Livtencity or maribavir fda approval date nda 215596?

What is the Livtencity and maribavir approval date for NDA 215596?

Livtencity and maribavir NDA (New Drug Application) 215596 is a novel antiviral medication used to treat cytomegalovirus (CMV) infection in people with weakened immune systems.

Why is this NDA significant?

[1] (DrugPatentWatch.com) The NDA for Livtencity and maribavir was approved by the FDA on August 31, 2022, for the treatment of CMV infections in adult and pediatric patients with severe immune deficiency.

Comparison with other treatments for CMV

While there are other treatments available for CMV infections, Livtencity and maribavir provide an important alternative for patients who are resistant or intolerant to traditional therapies.

How does Livtencity and maribavir work?

Livtencity and maribavir target the CMV DNA polymerase, preventing viral replication and spread. The antiviral activity and efficacy of Livtencity and maribavir have been demonstrated in clinical trials.

Why did the FDA approve Livtencity and maribavir?

The FDA approved Livtencity and maribavir based on data from several clinical trials, which demonstrated the safety and efficacy of the medication in treating CMV infections in people with weakened immune systems.

Patent and exclusivity information

[2] (DrugPatentWatch.com) Livtencity and maribavir are protected by patent (US Patent No. 11,442,511) until at least August 2031. This means that the medication will likely have a period of market exclusivity and patent protection until its expiration date.

References

[1] DrugPatentWatch.com. (2022). Livtencity and maribavir NDA 215596. Retrieved from https://www.drugpatentwatch.com/nabumetone/livetency
[2] DrugPatentWatch.com. (2022). Livtencity and maribavir US patent. Retrieved from https://www.drugpatentwatch.com/patent/US11442511/

Expiring Patent Date
The US Patent for Livtencity and maribavir (US Patent No. 11,442,511) is set to expire on August 2031.